论文部分内容阅读
目的:探讨血清HE4联合CA125检测诊断卵巢上皮性癌的临床意义。方法:以2009年3月～2011年10月收治的40例老年卵巢肿瘤为实验组,以30例健康体检者为对照组,检测两组的血清HE4和CA124并进行统计学分析。结果:实验组HE4阳性率为82.50%,CA125阳性率为75.00%,对照组HE4阳性0例,CA125阳性率为3.33%,两组阳性率差异有统计学意义(P<0.05)。实验组HE4值为(201.45±41.33)pmol/L,CA125值为(275.4±75.64)U/ml;对照组HE4值为(44.57±6.84)pmol/L,CA125值为(15.53±5.82)U/ml,两组HE4和CA125检测结果比较差异有统计学意义(P<0.05)。结论:血清HE4联合CA125检测诊断卵巢上皮性癌的阳性率高于单一指标检测,值得临床推广。
Objective: To investigate the clinical significance of serum HE4 combined with CA125 in the diagnosis of epithelial ovarian cancer. Methods: Forty elderly ovarian tumors from March 2009 to October 2011 were selected as the experimental group and 30 healthy controls as the control group. Serum levels of HE4 and CA124 in both groups were detected and statistically analyzed. Results: The positive rate of HE4 in experimental group was 82.50%, the positive rate of CA125 was 75.00%, the positive rate of CA4 in control group was 0, and the positive rate of CA125 was 3.33%. There was significant difference between the two groups (P <0.05). The HE4 value of the experimental group was (201.45 ± 41.33) pmol / L and the CA125 value was (275.4 ± 75.64) U / ml. The HE4 value of the control group was (44.57 ± 6.84) pmol / L and the CA125 value was (15.53 ± 5.82) ml. There was significant difference between the two groups in the detection results of HE4 and CA125 (P <0.05). Conclusion: The positive rate of serum HE4 combined with CA125 in the diagnosis of epithelial ovarian cancer is higher than that of single index, which deserves clinical promotion.